Hyperhidrosis Primary Focal Axilla Clinical Trial
Official title:
Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis: a Randomized Intra-individual Trial
Verified date | May 2023 |
Source | Bispebjerg Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial aims is to assess and compare treatment effect of microwave thermolysis and botulinum toxin A for axillary hyperhidrosis with focus on longevity. The investigators also aim to assess patient satisfaction and adverse reactions in relation to treatment.
Status | Completed |
Enrollment | 30 |
Est. completion date | April 24, 2023 |
Est. primary completion date | October 17, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject has provided written informed consent 2. Subject is 18 years of age or older 3. A unilateral HDSS score of 3 or 4 for each axilla 4. A gravimetric measurement of at least 50 mg/5 min for women and 100 mg/5 min for men in at least one axilla. The contralateral axilla should not be below 40 mg (women) and 80 mg (men). 5. Women of childbearing potential must be confirmed not pregnant by a negative u-HCG prior to study treatment and must use a safe contraceptive method at baseline. Exclusion Criteria: 1. Subjects with generalized hyperhidrosis 2. Medical condition or medications that may alter perspiration (e.g. metabolic, immunological or infectious diseases, antidepressants, opioids, adrenergic/cholinergic drugs) 3. Daily use of systemic or topical antibiotics and/or steroids in axillae at the time of inclusion 4. Topical treatments for axillary hyperhidrosis (anti-perspirants are allowed except for visit days) 5. Abnormal skin (e.g. rash, infection, dermatitis) in the axilla at the time of inclusion 6. Breast tissue in the axillae 7. Treatment with Isotretinoin within the past 6 months 8. Axillary laser or IPL treatment within the past 6 months 9. Botulinum toxin-injections in the axillae within the past 12 months prior to baseline 10. Known allergies to botulinum toxin, iodine, lidocaine or adrenaline 11. Prior axillary surgery 12. Limited motion in the shoulder joint or neurologic deficit in upper limb 13. History of diseases resulting in muscle weakness (ALS, Lou Gehrig's), dysphagia (Myasthenia Gravis or Lambert Eaton Syndrome) or respiratory compromise 14. Axillary lymph node enlargement or -removal or lymphedema in either upper limb 15. History of hidradenitis suppurativa or history of reoccurring infections/abscesses 16. History of breast cancer 17. Electronic device implant 18. If female; lactating, pregnant or planning on becoming pregnant during the study 19. Non-eligibility at the discretion of the investigator (e.g. non-compliance, unavailability or other reasons the subject is not believed to be able to comply with the clinical trial protocol) |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Dermatology, Bispebjerg Hospital | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Merete Haedersdal |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjective change in axillary sweat | Unilateral sweat change from baseline to 6 months follow-up assessed by Hyperhidrosis Disease Severity Scale | Baseline - 6 months | |
Secondary | Objective change in axillary sweat | Unilateral sweat change from baseline to 6 months follow-up assessed by gravimetric test | Baseline - 6 months | |
Secondary | Patient Satisfaction | Unilateral patient satisfaction 6 and 12 months after treatments assessed on a 3-point Likert Scale (unsatisfied - neutral - satisfied) | Baseline - 6 months - 12 months | |
Secondary | Adverse reactions | Unilateral evaluation of adverse reactions after treatments | Baseline - 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05860972 -
Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency
|
N/A | |
Enrolling by invitation |
NCT04227691 -
Treatment of Axillary Hyperhidrosis With Long-pulsed Nd:YAG Laser or IPL
|
N/A | |
Completed |
NCT03760198 -
Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis
|
Phase 3 |